Title: Level Of Interleukin 17 In Inflammatory Bowel Disease And Its Relation With Disease
Activity
Version: 2 Date: 20 Dec 2023
Reviewer's report:
I appreciate the opportunity to review the manuscript titled "Interleukin 17 Level in
Inflammatory Bowel Disease and Its Relationship with Disease Activity."
This is a cross-sectional study conducted at a single center, with the primary objective of
detecting IL-17 levels in the serum of patients with inflammatory bowel disease (IBD) and
analyzing their relationship with disease activity.
After a thorough review of the manuscript, I would like to highlight the following considerations:
1. While the manuscript's title aligns with the research objective, it does not adequately reflect
the study's main results.
3. It is important to avoid mixing patients with ulcerative colitis and Crohn's disease in the data
analysis, as evidenced in Table 2, as these are two entities with different clinical profiles.
4. It is noteworthy that Table 2 does not show significant differences in biochemical parameters
between IBD patients and controls. This lack of differentiation may be due, once again, to the
grouping of patients with ulcerative colitis and Crohn's disease in the same group.
5. I suggest considering the evaluation of clinical, biochemical, endoscopic, and histological
activity in separate groups for ulcerative colitis and Crohn's disease, along with an analysis of
their relationship with serological markers and IL-17 levels.
6. The absence of information about the method of subject recruitment in the study could
introduce selection bias that may affect the representativeness of the sample.
7. Given that the control group consists of only 21 healthy volunteers, it should be noted that
this may limit the study's ability to detect significant differences compared to the IBD groups,
especially if there is not adequate matching in terms of demographic characteristics.
8. The lack of longitudinal data in the study prevents obtaining a more comprehensive
understanding of the relationship between IL-17 levels and the progression of disease activity
over time.
9. It would be beneficial to include more details about the validation and reliability of the ELISA
tests used to measure IL-17 levels, including information about intra- and inter-assay variability.
10. The absence of an association between serum IL-17 levels and disease activity raises
questions about the validity of the results of the ROC curve analysis.
The study has a solid foundation, but there are some inconsistencies and important
considerations that need to be addressed to enhance the validity and interpretation of the results.
Title: Level Of Interleukin 17 In Inflammatory Bowel Disease And Its Relation With Disease
Activity
Version: 2 Date: 20 Dec 2023
Reviewer's report:
I appreciate the opportunity to review the manuscript titled "Interleukin 17 Level in
Inflammatory Bowel Disease and Its Relationship with Disease Activity."
This is a cross-sectional study conducted at a single center, with the primary objective of
detecting IL-17 levels in the serum of patients with inflammatory bowel disease (IBD) and
analyzing their relationship with disease activity.
After a thorough review of the manuscript, I would like to highlight the following considerations:
1. While the manuscript's title aligns with the research objective, it does not adequately reflect
the study's main results.
3. It is important to avoid mixing patients with ulcerative colitis and Crohn's disease in the data
analysis, as evidenced in Table 2, as these are two entities with different clinical profiles.
4. It is noteworthy that Table 2 does not show significant differences in biochemical parameters
between IBD patients and controls. This lack of differentiation may be due, once again, to the
grouping of patients with ulcerative colitis and Crohn's disease in the same group.
5. I suggest considering the evaluation of clinical, biochemical, endoscopic, and histological
activity in separate groups for ulcerative colitis and Crohn's disease, along with an analysis of
their relationship with serological markers and IL-17 levels.
6. The absence of information about the method of subject recruitment in the study could
introduce selection bias that may affect the representativeness of the sample.
7. Given that the control group consists of only 21 healthy volunteers, it should be noted that
this may limit the study's ability to detect significant differences compared to the IBD groups,
especially if there is not adequate matching in terms of demographic characteristics.
8. The lack of longitudinal data in the study prevents obtaining a more comprehensive
understanding of the relationship between IL-17 levels and the progression of disease activity
over time.
9. It would be beneficial to include more details about the validation and reliability of the ELISA
tests used to measure IL-17 levels, including information about intra- and inter-assay variability.
10. The absence of an association between serum IL-17 levels and disease activity raises
questions about the validity of the results of the ROC curve analysis.
The study has a solid foundation, but there are some inconsistencies and important
considerations that need to be addressed to enhance the validity and interpretation of the results.
Please review this paper.
user
Title: Level Of Interleukin 17 In Inflammatory Bowel Disease And Its Relation With Disease
Activity
Version: 2 Date: 20 Dec 2023
Reviewer's report:
I appreciate the opportunity to review the manuscript titled "Interleukin 17 Level in
Inflammatory Bowel Disease and Its Relationship with Disease Activity."
This is a cross-sectional study conducted at a single center, with the primary objective of
detecting IL-17 levels in the serum of patients with inflammatory bowel disease (IBD) and
analyzing their relationship with disease activity.
After a thorough review of the manuscript, I would like to highlight the following considerations:
1. While the manuscript's title aligns with the research objective, it does not adequately reflect
the study's main results.
3. It is important to avoid mixing patients with ulcerative colitis and Crohn's disease in the data
analysis, as evidenced in Table 2, as these are two entities with different clinical profiles.
4. It is noteworthy that Table 2 does not show significant differences in biochemical parameters
between IBD patients and controls. This lack of differentiation may be due, once again, to the
grouping of patients with ulcerative colitis and Crohn's disease in the same group.
5. I suggest considering the evaluation of clinical, biochemical, endoscopic, and histological
activity in separate groups for ulcerative colitis and Crohn's disease, along with an analysis of
their relationship with serological markers and IL-17 levels.
6. The absence of information about the method of subject recruitment in the study could
introduce selection bias that may affect the representativeness of the sample.
7. Given that the control group consists of only 21 healthy volunteers, it should be noted that
this may limit the study's ability to detect significant differences compared to the IBD groups,
especially if there is not adequate matching in terms of demographic characteristics.
8. The lack of longitudinal data in the study prevents obtaining a more comprehensive
understanding of the relationship between IL-17 levels and the progression of disease activity
over time.
9. It would be beneficial to include more details about the validation and reliability of the ELISA
tests used to measure IL-17 levels, including information about intra- and inter-assay variability.
10. The absence of an association between serum IL-17 levels and disease activity raises
questions about the validity of the results of the ROC curve analysis.
The study has a solid foundation, but there are some inconsistencies and important
considerations that need to be addressed to enhance the validity and interpretation of the results.
assistant